C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in Sweden
The aim of this study was to evaluate the synthetic C6 peptide test as a first-line test in a two-tiered scheme for Borrelia serology in a clinically well-characterized population of patients with Lyme borreliosis in Kalmar County, Sweden. The study population consisted of a prospective group (n=200), a control group (n=255), and a retrospective group (n=29). The test panel consisted of the Immune
